Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Osilodrostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 known ✓ | P15538 | 7/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 17/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 8/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | CYP17A1 | P05093 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Osilodrostat SCHEMBL30395982 | 1.00 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| Osilodrostat SCHEMBL1037475 | 1.00 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| Osilodrostat SCHEMBL12460772 | 1.00 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| Osilodrostat SCHEMBL14761109 | 0.99 | CYP11B2 (0.98) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| Osilodrostat SCHEMBL16280483 | 0.99 | CYP11B2 (0.98) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| Osilodrostat SCHEMBL13837602 | 0.93 | CYP11B2 (0.87) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| Osilodrostat SCHEMBL15128942 | 0.93 | CYP11B2 (0.87) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| Osilodrostat SCHEMBL30395736 | 0.93 | CYP11B2 (0.87) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| SCHEMBL1039611 | 0.93 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| SCHEMBL1040487 | 0.92 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835646-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-09-16 | — | — | US | claimed |
| US-8314097-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | claimed |
| CN-107207518-B | Process for producing fused imidazole derivative | 雷科尔达蒂股份公司 | 2021-03-30 | — | — | CN | disclosed |
| EP-3250555-B1 | PROCESS FOR THE PRODUCTION OF CONDENSED IMIDAZOLO DERIVATIVES | RECORDATI AG (CH) | 2021-03-03 | — | — | EP | disclosed |
| EP-3250555-B1 | PROCESS FOR THE PRODUCTION OF CONDENSED IMIDAZOLO DERIVATIVES | RECORDATI AG (CH) | 2021-03-03 | — | — | EP | disclosed |
| US-10556869-B2 | Process for the production of condensed imidazolo derivatives | NOVARTIS AG (CH) | 2020-02-11 | — | — | US | disclosed |
| US-10556869-B2 | Process for the production of condensed imidazolo derivatives | NOVARTIS AG (CH) | 2020-02-11 | — | — | US | disclosed |
| US-20180002292-A1 | PROCESS FOR THE PRODUCTION OF CONDENSED IMIDAZOLO DERIVATIVES | RECORDATI AG (CH) | 2018-01-04 | — | — | US | disclosed |
| US-20180002292-A1 | PROCESS FOR THE PRODUCTION OF CONDENSED IMIDAZOLO DERIVATIVES | RECORDATI AG (CH) | 2018-01-04 | — | — | US | disclosed |
| EP-3250555-A1 | PROCESS FOR THE PRODUCTION OF CONDENSED IMIDAZOLO DERIVATIVES | Novartis AG (CH) | 2017-12-06 | — | — | EP | disclosed |
| WO-2016120821-A1 | PROCESS FOR THE PRODUCTION OF CONDENSED IMIDAZOLO DERIVATIVES | NOVARTIS AG (CH) | 2016-08-04 | — | — | WO | disclosed |
| US-8314097-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20120277215-A1 | Organic Compounds | RECORDATI AG (CH) | 2012-11-01 | — | — | US | disclosed |
| EP-2507234-A1 | IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | Novartis AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011064376-A1 | IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2011-06-03 | — | — | WO | disclosed |
| EP-2270011-A1 | Condensed imidazolo derivatives for the inhibition of aromatase | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| EP-2256118-A1 | Condensed imidazolo derivatives for the inhibition of aromatase | Novartis AG (CH) | 2010-12-01 | — | — | EP | disclosed |
| EP-1919916-A1 | CONDENSED IMIDAZOLO DERIVATIVES FOR THE INHIBITION OF ALDOSTERONE SYNTHASE AND AROMATASE | Novartis AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| US-20070049616-A1 | Organic compounds | RECORDATI AG (CH) | 2007-03-01 | — | — | US | disclosed |
| WO-2007024945-A1 | CONDENSED IMIDAZOLO DERIVATIVES FOR THE INHIBITION OF ALDOSTERONE SYNTHASE AND AROMATASE | NOVARTIS AG (CH) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049616-A1 | Organic compounds | CYP19A1, CYP17A1, HSD17B11 | CYP11B1 5/4885CYP11B2 14/4885CYP19A1 1/4885 |
| US-20180002292-A1 | PROCESS FOR THE PRODUCTION OF CONDENSED IMIDAZOLO DERIVATIVES | IPO4, IPO7, IPO9 | CYP11B1 351/4885CYP11B2 211/4885CYP19A1 2026/4885 |
| US-10556869-B2 | Process for the production of condensed imidazolo derivatives | IPO4, IPO7, IPO9 | CYP11B1 351/4885CYP11B2 211/4885CYP19A1 2026/4885 |
| US-20120277215-A1 | Organic Compounds | CYP19A1, CYP17A1, HSD17B11 | CYP11B1 5/4885CYP11B2 14/4885CYP19A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.